Menatetrenone versus alfacalcidol in the treatment of chinese postmenopausal women with osteoporosis: A multicenter, randomized, double-blinded, double-dummy, positive drug-controlled clinical trial

18Citations
Citations of this article
71Readers
Mendeley users who have this article in their library.

Abstract

Objective: To evaluate whether the efficacy and safety of menatetrenone for the treatment of osteoporosis is noninferior to alfacalcidol in Chinese postmenopausal women. Method: This multicenter, randomized, double-blinded, double-dummy, noninferiority, positive drug-controlled clinical trial was conducted in five Chinese sites. Eligible Chinese women with postmenopausal osteoporosis (N=236) were randomized to Group M or Group A and received menatetrenone 45 mg/day or alfacalcidol 0.5 μg/day, respectively, for 1 year. Additionally, all patients received calcium 500 mg/day. Posttreatment bone mineral density (BMD), new fracture onsets, and serum osteocalcin (OC) and undercarboxylated OC (ucOC) levels were compared with the baseline value in patients of both groups. Results: A total of 213 patients (90.3%) completed the study. After 1 year of treatment, BMD among patients in Group M significantly increased from baseline by 1.2% and 2.7% at the lumbar spine and trochanter, respectively (P,0.001); and the percentage increase of BMD in Group A was 2.2% and 1.8%, respectively (P,0.001). No difference was observed between groups. There were no changes in femoral neck BMD in both groups. Two patients (1.9%, 2/108) in Group M and four patients (3.8%, 4/105) in Group A had new fracture onsets (P.0.05). In Group M, OC and ucOC decreased from baseline by 38.7% and 82.3%, respectively (P,0.001). In Group A, OC and ucOC decreased by 25.8% and 34.8%, respectively (P,0.001). Decreases in serum OC and ucOC were more obvious in Group M than in Group A (P,0.001). The safety profile of menatetrenone was similar to alfacalcidol. Conclusion: Menatetrenone is an effective and safe choice in the treatment of postmenopausal osteoporosis in Chinese women. © 2014 Jiang et al.

Cite

CITATION STYLE

APA

Jiang, Y., Zhang, Z. L., Zhang, Z. L., Zhu, H. M., Wu, Y. Y., Cheng, Q., … Meng, X. W. (2014). Menatetrenone versus alfacalcidol in the treatment of chinese postmenopausal women with osteoporosis: A multicenter, randomized, double-blinded, double-dummy, positive drug-controlled clinical trial. Clinical Interventions in Aging, 9, 121–127. https://doi.org/10.2147/CIA.S54107

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free